Jones Financial Companies Lllp Boosts Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Jones Financial Companies Lllp grew its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 95.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,212 shares of the company’s stock after buying an additional 2,059 shares during the quarter. Jones Financial Companies Lllp’s holdings in Elanco Animal Health were worth $51,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health during the third quarter worth approximately $35,000. SRS Capital Advisors Inc. grew its holdings in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after buying an additional 3,411 shares in the last quarter. Blue Trust Inc. grew its holdings in Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after buying an additional 1,894 shares in the last quarter. Spire Wealth Management grew its holdings in Elanco Animal Health by 107.4% in the 4th quarter. Spire Wealth Management now owns 7,776 shares of the company’s stock valued at $94,000 after buying an additional 4,026 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Elanco Animal Health in the 4th quarter valued at $142,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. UBS Group decreased their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Price Performance

ELAN stock opened at $10.82 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market capitalization of $5.35 billion, a P/E ratio of 27.04, a P/E/G ratio of 2.50 and a beta of 1.44. The business’s 50-day moving average is $11.41 and its two-hundred day moving average is $12.67. Elanco Animal Health Incorporated has a 1 year low of $10.03 and a 1 year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business earned $0.08 EPS. Elanco Animal Health’s revenue for the quarter was down 1.4% on a year-over-year basis. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now owns 111,459 shares in the company, valued at $1,136,881.80. The trade was a 9.86 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.